The pharmacokinetics of peginterferon alfa-2a and ribavirin in African American, Hispanic and Caucasian patients with chronic hepatitis C

Alimentary Pharmacology and Therapeutics

Volumn 35, Issue 10, 2012, Pages 1209-1220

  Brennan, B J ^a   Morcos, P N ^a   Wang, K ^a   Blotner, S D ^a   Morrison, R ^b   Hagedorn, C H ^c   Marbury, T C ^d   Sulkowski, M ^e   Grippo, J F ^a  

^a HOFFMANN LA ROCHE INC   (United States)

^b Comprehensive Clinical Development Northwest ^*  (United States)

^c UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^d ORLANDO CLINICAL RESEARCH CENTER   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN;

ADULT; AFRICAN AMERICAN; AGED; AREA UNDER THE CURVE; ARTICLE; CAUCASIAN; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HISPANIC; HUMAN; MALE; MATHEMATICAL ANALYSIS; MAXIMUM PLASMA CONCENTRATION; OPEN STUDY; PARALLEL DESIGN; PRIORITY JOURNAL; RACE DIFFERENCE; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AFRICAN AMERICANS; ANTIVIRAL AGENTS; AREA UNDER CURVE; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOTYPE; HEPATITIS C, CHRONIC; HISPANIC AMERICANS; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN;

EID: 84859922267     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2012.05079.x     Document Type: Article

References (55)

1. Kershenobich D, Razavi HA, Sanchez-Avila JF, et al,. Trends and projections of hepatitis C virus epidemiology in Latin America. Liver Int 2011; 31 (Suppl. 2): 18-29.
2. Cornberg M, Razavi HA, Alberti A, et al,. A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int 2011; 31 (Suppl. 2): 30-60.
3. Sievert W, Altraif I, Razavi HA, et al,. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int 2011; 31 (Suppl. 2): 61-80.
4. Afdhal NH,. The natural history of hepatitis C. Semin Liver Dis 2004; 24 (Suppl. 2): 3-8. (Pubitemid 39180700)
5. Masarone M, Persico M,. Antiviral therapy: why does it fail in HCV-related chronic hepatitis? Expert Rev Anti Infect Ther 2011; 9: 535-43.
6. Ilyas JA, Vierling JM,. An overview of emerging therapies for the treatment of chronic hepatitis C. Clin Liver Dis 2011; 15: 515-36.
7. McGlynn KA, London WT,. The global epidemiology of hepatocellular carcinoma: present and future. Clin Liver Dis 2011; 15: 223 -43.
8. Ponziani FR, Gasbarrini A, Pompili M, Burra P, Fagiuoli S,. Management of hepatitis C virus infection recurrence after liver transplantation: an overview. Transplant Proc 2011; 43: 291-5.
9. Hanish SI, Knechtle SJ,. Liver transplantation for the treatment of hepatocellular carcinoma. Oncology (Williston Park) 2011; 25: 752-7.
10. Strader DB, Wright T, Thomas DL, Seeff LB, American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39: 1147-71. (Pubitemid 38428955)
11. Hadziyannis SJ, Sette H Jr, Morgan TR, et al,. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-55.
12. Zeuzem S, Diago M, Gane E, et al,. Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology 2004; 127: 1724-32. (Pubitemid 39575851)
13. Zeuzem S, Pawlotsky JM, Lukasiewicz E, et al,. International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C. J Hepatol 2005; 43: 250-7. (Pubitemid 40956877)
14. Mangia A, Mottola L,. Treatment of non-genotype 1 hepatitis C virus patients. Curr Gastroenterol Rep 2012; 14: 87-93.
15. Muir AJ, Hu KQ, Gordon SC, et al,. Hepatitis C treatment among racial and ethnic groups in the IDEAL trial. J Viral Hepat 2011; 18: e134-43.
16. Manka C, Gomes R, Reviere R, Lee C,. Treatment options for hepatitis C and the rationale for low response rates in African Americans. J Natl Med Assoc 2009; 101: 604-8.
17. Manns MP, McHutchison JG, Gordon SC, et al,. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65. (Pubitemid 32913521)
18. von Wagner M, Huber M, Berg T, et al,. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005; 129: 522-7. (Pubitemid 41096640)
19. Layden-Almer JE, Ribeiro RM, Wiley T, Perelson AS, Layden TJ,. Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin. Hepatology 2003; 37: 1343-50. (Pubitemid 36667314)
20. Conjeevaram HS, Fried MW, Jeffers LJ, et al,. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 2006; 131: 470-7. (Pubitemid 44142464)
21. Hepburn MJ, Hepburn LM, Cantu NS, Lapeer MG, Lawitz EJ,. Differences in treatment outcome for hepatitis C among ethnic groups. Am J Med 2004; 117: 163-8. (Pubitemid 39055867)
22. Rodriguez-Torres M, Jeffers LJ, Sheikh MY, et al,. Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C. N Engl J Med 2009; 360: 257-67.
23. Jeffers LJ, Cassidy W, Howell CD, Hu S, Reddy KR,. Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology 2004; 39: 1702-8. (Pubitemid 38702672)
24. Victrelis (boceprevir) capsules. Merck. Available at:. 2011. Accessed February 1, 2012.
25. Incivek (telaprevir) film coated tablets. Vertex. Available at:. 2011. Accessed February 1, 2012.
26. Tungol A, Rademacher K, Schafer JA,. Formulary management of the protease inhibitors boceprevir and telaprevir for chronic hepatitis C virus. J Manag Care Pharm 2011; 17: 685-94.
27. Sherman KE, Flamm SL, Afdhal NH, et al,. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365: 1014-24.
28. Bacon BR, Gordon SC, Lawitz E, et al,. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-17.
29. Zeuzem S, Andreone P, Pol S, et al,. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-28.
30. Poordad F, McCone J Jr, Bacon BR, et al,. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-206.
31. Jacobson IM, McHutchison JG, Dusheiko G, et al,. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-16.
32. Rosen HR, Weston SJ, Im K, et al,. Selective decrease in hepatitis C virus-specific immunity among African Americans and outcome of antiviral therapy. Hepatology 2007; 46: 350-8. (Pubitemid 47344769)
33. Sugimoto K, Stadanlick J, Ikeda F, et al,. Influence of ethnicity in the outcome of hepatitis C virus infection and cellular immune response. Hepatology 2003; 37: 590-9. (Pubitemid 36258781)
34. Pos Z, Selleri S, Spivey TL, et al,. Genomic scale analysis of racial impact on response to IFN-alpha. Proc Natl Acad Sci USA 2010; 107: 803-8.
35. Donlin MJ, Cannon NA, Aurora R, et al,. Contribution of genome-wide HCV genetic differences to outcome of interferon-based therapy in Caucasian American and African American patients. PLoS ONE 2010; 5: e9032.
36. Ramcharran D, Wahed AS, Conjeevaram HS, et al,. Associations between serum lipids and hepatitis C antiviral treatment efficacy. Hepatology 2010; 52: 854-63.
37. Li S, Hu P, Zhang QQ, et al,. Single nucleotide polymorphisms of the IL28B and sustained virologic response of patients with chronic hepatitis C to PEG-interferon/ribavirin therapy: a meta-analysis: meta-analysis of IL28B. Hepat Mon 2011; 11: 163-72.
38. Suppiah V, Moldovan M, Ahlenstiel G, et al,. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41: 1100-4.
39. Tanaka Y, Nishida N, Sugiyama M, et al,. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-9.
40. Rauch A, Kutalik Z, Descombes P, et al,. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010; 138: 1338-45.
41. Thompson AJ, Muir AJ, Sulkowski MS, et al,. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010; 139: 120-9.
42. Thomas DL, Thio CL, Martin MP, et al,. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461: 798-801.
43. McCarthy JJ, Li JH, Thompson A, et al,. Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology 2010; 138: 2307-14.
44. Ge D, Fellay J, Thompson AJ, et al,. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
45. Cavalcante LN, Abe-Sandes K, Angelo AL, et al,. IL28B polymorphisms are markers of therapy response and are influenced by genetic ancestry in chronic hepatitis C patients from an admixed population. Liver Int 2012; 32: 476-86.
46. Fried MW, Shiffman ML, Reddy KR, et al,. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
47. Glue P,. The clinical pharmacology of ribavirin. Semin Liver Dis 1999; 19 (Suppl. 1): 17-24. (Pubitemid 29220816)
48. Howell CD, Dowling TC, Paul M, et al,. Peginterferon pharmacokinetics in African American and Caucasian American patients with hepatitis C virus genotype 1 infection. Clin Gastroenterol Hepatol 2008; 6: 575-83.
49. Wade JR, Snoeck E, Duff F, Lamb M, Jorga K,. Pharmacokinetics of ribavirin in patients with hepatitis C virus. Br J Clin Pharmacol 2006; 62: 710-4. (Pubitemid 44749548)
50. Breilh D, Foucher J, Castera L, et al,. Impact of ribavirin plasma level on sustained virological response in patients treated with pegylated interferon and ribavirin for chronic hepatitis C. Aliment Pharmacol Ther 2009; 30: 487-94.
51. Copegus (ribavirin) capsules. Hoffmann-La Roche. Available at:. 2012. Accessed February 1, 2012.
52. Fattovich G, Covolo L, Bibert S, et al,. IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C. Aliment Pharmacol Ther 2011; 33: 1162-72.
53. Akuta N, Suzuki F, Hirakawa M, et al,. Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology 2010; 52: 421-9.
54. Fried MW, Buti M, Dore GJ, et al,. Efficacy and safety of TMC435 in combination with peginterferon-alfa-2a and ribavirin in treatment-naive genotype-1 HCV patients: 24-week interim results from the PILLAR study. Hepatology 2010; 52: 57.
55. Poordad F, Bronowicki JP, Gordon SC, et al,. IL28B polymorphism predicts virologic response in patients with hepatitis c genotype 1 treated with boceprevir combination therapy. J Hepatol 2011; 54: S6.